読み込み中
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
前日終値
$1.58
−$0.10 · -5.95%
日中の時刻はETです。市場データは遅延する場合があります。
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
日中レンジ
現在 $1.58
52週レンジ
現在 $1.58
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
74
割安
センチメント
49
まちまち
リスク
67
高リスク
モメンタム
22
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
日中レンジ
現在 $1.58
52週レンジ
現在 $1.58
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$4.30
上昇余地（172.15%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI202.5万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM63.79万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF60.54万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO26.11万0.00%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO26.07万0.00%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC8.21万0.01%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM6万0.05%1.17億 USD0.73%$15.9402+0.25%
Vanguard Russell 2000 Growth ETFVTWG5.16万0.00%17億 USD0.06%$260.49+0.91%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Growth ETFVTWGAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
